Global Breast Cancer Screening Test Market 2023-2029
Description
Global Breast Cancer Screening Test Market 2023-2029
Breast cancer screening tests are necessary because breast cancer is a common type of cancer that affects women all over the world. Early detection and treatment of breast cancer can significantly improve a woman's chances of survival and reduce the need for more aggressive treatments. Breast cancer screening tests are recommended for women who are at average risk of developing breast cancer, as well as those who are at high risk due to factors such as family history, genetic mutations, or previous breast cancer diagnoses. According to the latest estimates, the global breast cancer screening test market is set to achieve an incremental growth of USD 1.6 billion, accelerating at a CAGR of almost 8.04% during the forecast period 2023-2029.
The report covers market size and growth, segmentation, regional breakdowns, competitive landscape, trends and strategies for global breast cancer screening test market. It presents a quantitative analysis of the market to enable stakeholders to capitalize on the prevailing market opportunities. The report also identifies top segments for opportunities and strategies based on market trends and leading competitors’ approaches.
This industry report offers market estimates and forecasts of the global market, followed by a detailed analysis of the test, and region. The global market for breast cancer screening test can be segmented by test: genomic tests, imaging test. In 2022, the imaging test segment made up the largest share of revenue generated by the breast cancer screening test market. Breast cancer screening test market is further segmented by region: North America, Europe, Asia-Pacific, MEA (Middle East and Africa), Latin America. North America was the largest contributor to the global breast cancer screening test market in 2022.
The imaging test market is further segmented into mammograms, ultrasound, MRI, tomography, others. Among these, the mammograms segment was accounted for the highest revenue generator in 2022.
Market Segmentation
By test: genomic tests, imaging test
By region: North America, Europe, Asia-Pacific, MEA (Middle East and Africa), Latin America
The report also provides analysis of the key companies of the industry and their detailed company profiles including Carestream Health Inc., F Hoffmann-LA Roche Ltd., Fujifilm Holdings Corporation, GE Healthcare, Hologic, Inc., Koninklijke Philips N.V., Myriad Genetics Inc., Nanostring Technologies Inc., Quest Diagnostics Incorporated, Siemens Healthineers AG, among others. In this report, key players and their strategies are thoroughly analyzed to understand the competitive outlook of the market.
Scope of the Report
Breast cancer screening tests are necessary because breast cancer is a common type of cancer that affects women all over the world. Early detection and treatment of breast cancer can significantly improve a woman's chances of survival and reduce the need for more aggressive treatments. Breast cancer screening tests are recommended for women who are at average risk of developing breast cancer, as well as those who are at high risk due to factors such as family history, genetic mutations, or previous breast cancer diagnoses. According to the latest estimates, the global breast cancer screening test market is set to achieve an incremental growth of USD 1.6 billion, accelerating at a CAGR of almost 8.04% during the forecast period 2023-2029.
The report covers market size and growth, segmentation, regional breakdowns, competitive landscape, trends and strategies for global breast cancer screening test market. It presents a quantitative analysis of the market to enable stakeholders to capitalize on the prevailing market opportunities. The report also identifies top segments for opportunities and strategies based on market trends and leading competitors’ approaches.
This industry report offers market estimates and forecasts of the global market, followed by a detailed analysis of the test, and region. The global market for breast cancer screening test can be segmented by test: genomic tests, imaging test. In 2022, the imaging test segment made up the largest share of revenue generated by the breast cancer screening test market. Breast cancer screening test market is further segmented by region: North America, Europe, Asia-Pacific, MEA (Middle East and Africa), Latin America. North America was the largest contributor to the global breast cancer screening test market in 2022.
The imaging test market is further segmented into mammograms, ultrasound, MRI, tomography, others. Among these, the mammograms segment was accounted for the highest revenue generator in 2022.
Market Segmentation
By test: genomic tests, imaging test
By region: North America, Europe, Asia-Pacific, MEA (Middle East and Africa), Latin America
The report also provides analysis of the key companies of the industry and their detailed company profiles including Carestream Health Inc., F Hoffmann-LA Roche Ltd., Fujifilm Holdings Corporation, GE Healthcare, Hologic, Inc., Koninklijke Philips N.V., Myriad Genetics Inc., Nanostring Technologies Inc., Quest Diagnostics Incorporated, Siemens Healthineers AG, among others. In this report, key players and their strategies are thoroughly analyzed to understand the competitive outlook of the market.
Scope of the Report
- To analyze and forecast the market size of the global breast cancer screening test market.
- To classify and forecast the global breast cancer screening test market based on test, region.
- To identify drivers and challenges for the global breast cancer screening test market.
- To examine competitive developments such as mergers & acquisitions, agreements, collaborations and partnerships, etc., in the global breast cancer screening test market.
- To identify and analyze the profile of leading players operating in the global breast cancer screening test market.
- Gain a reliable outlook of the global breast cancer screening test market forecasts from 2023 to 2029 across scenarios.
- Identify growth segments for investment.
- Stay ahead of competitors through company profiles and market data.
- The market estimate for ease of analysis across scenarios in Excel format.
- Strategy consulting and research support for three months.
- Print authentication provided for the single-user license.
Table of Contents
78 Pages
- PART 1. INTRODUCTION
- Report description
- Objectives of the study
- Market segment
- Years considered for the report
- Currency
- Key target audience
- PART 2. METHODOLOGY
- PART 3. EXECUTIVE SUMMARY
- PART 4. MARKET OVERVIEW
- Introduction
- Drivers
- Restraints
- PART 5. MARKET BREAKDOWN BY TEST
- Genomic tests
- Imaging test
- PART 6. MARKET BREAKDOWN BY REGION
- North America
- Europe
- Asia-Pacific
- MEA (Middle East and Africa)
- Latin America
- PART 7. KEY COMPANIES
- Carestream Health Inc.
- F Hoffmann-LA Roche Ltd.
- Fujifilm Holdings Corporation
- GE Healthcare
- Hologic, Inc.
- Koninklijke Philips N.V.
- Myriad Genetics Inc.
- Nanostring Technologies Inc.
- Quest Diagnostics Incorporated
- Siemens Healthineers AG
- DISCLAIMER
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
